• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Hydrocortisone does not improve bronchopulmonary dysplasia outcomes in pre-term babies

byBoaz WongandHarsh Shah
March 28, 2022
in Emergency, Pediatrics, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In extremely preterm infants on mechanical ventilation, hydrocortisone was unable to improve 36-week survival or 2-year survival without neurodevelopmental impairment compared to placebo.

Evidence Rating Level: 1 (Excellent)    

Study Rundown: Extremely preterm babies are at high risk for bronchopulmonary dysplasia (BPD), which is damage to the lungs caused by mechanical ventilation. Some evidence suggests that the administration of anti-inflammatory medications may reduce alveolar damage. To investigate this, infants born extremely preterm (< 30 weeks gestational age) who received mechanical ventilation were randomized to either receive hydrocortisone tapered over a period of 10 days or a placebo. Primary outcomes measures were efficacy (survival without BPD at 36 weeks postmenstrual age) and safety (survival without moderate or severe neurodevelopmental impairment at 2 years follow-up). Secondary endpoints assessed standard complications and growth measures following extremely pre-term delivery such as successful extubation and respiratory status. The study found that hydrocortisone did not improve the proportion of patients who survived without bronchopulmonary dysplasia at 36 weeks, nor the proportion of infants without neurodevelopmental impairment at 2 years compared to placebo. However, hydrocortisone was able to improve several secondary outcomes including an increased rate of successful extubation and shorter time on mechanical ventilation. With respect to adverse events, hydrocortisone treatment increased the frequency of hypertension. Taken together, the study does not support the use of hydrocortisone to improve BPD outcomes in extremely preterm infants. The results of this study are limited potential confounding by dexamethasone administration across both groups and its stringent inclusion criteria.

Click to read the study in NEJM 

Relevant Reading: Effect of systemic hydrocortisone initiated 7 to 14 days after birth in ventilated preterm infants on mortality and neurodevelopment at 2 years’ corrected age: follow-up of a randomized clinical trial

In-Depth [randomized controlled trial]: In this large, multicenter, phase 3 randomized control trial, 800 infants born extremely preterm (< 30 weeks gestational age) and intubated for at least 7 days were enrolled. Infants were randomized in a 1:1 ratio to either receive oral or intravenous hydrocortisone (4 mg/kg bodyweight) tapered over 10 days or a placebo. The primary outcome of this study was divided into efficacy and safety measures. For efficacy, infants were assessed at 36 weeks for survival without moderate or severe bronchopulmonary dysplasia (BPD) defined by supplemental oxygen use, ventilation requirements, and an ambient-air challenge. For safety, survival at 22-26 months of corrected age without moderate or severe neurodevelopmental impairment was assessed according to Bayley Scales of Infant and Toddler Development-III (Bayley-III), Gross Motor Function Classification System (GMCFS), and vision/hearing examination. Secondary outcomes assessed standard progression from mechanical intubation such as rate and time to extubation, as well as severe adverse events. Most statistical differences were assessed by robust Poisson regression to obtain adjusted relative risk estimates. The study found that at 36 weeks of post-menstrual age, 16.6% of patients in the hydrocortisone group survived without moderate or severe BPD, which was not statistically different compared to 13.2% in the placebo group (adjusted rate ratio [ARR], 1.27; 95% confidence interval [CI], 0.93-1.74). Similarly, in the safety measure, 36.9% of infants receiving hydrocortisone survived without moderate or severe neurodevelopmental impairment, which was not statistically different from 37.3% in the placebo group (ARR, 0.98; 95% CI, 0.81-1.18). Hydrocortisone was able to improve a few secondary measures including an increased rate of successful extubation (44.7% vs. 33.6%) and fewer days of ventilation (mean, 37 days vs. 40 days). For severe adverse events, 4.3% of infants receiving hydrocortisone experienced hypertension, which was significantly greater than the placebo group (ARR, 4.27; 95% CI, 1.45-12.55). All other severe adverse events were similar between the two groups. Overall, the study does not support the use of hydrocortisone in extremely preterm infants on mechanical ventilation owing to its inability to improve efficacy and safety outcomes relating to BPD.

Image: PD

RELATED REPORTS

#VisualAbstract: Expectant management of patent ductus arteriosus in extremely premature infants was non-inferior to early ibuprofen treatment

Laryngeal mask airway is suitable method for surfactant administration in infants with respiratory distress syndrome

Organizational factors increase risk of unplanned extubation in neonatal intensive care unit

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bronchopulmonary dysplasia (BPD)hydrocortisoneneurodevelopmental outcomespretermpreterm infant
Previous Post

Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer

Next Post

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

RelatedReports

#VisualAbstract: Expectant management of patent ductus arteriosus in extremely premature infants was non-inferior to early ibuprofen treatment
StudyGraphics

#VisualAbstract: Expectant management of patent ductus arteriosus in extremely premature infants was non-inferior to early ibuprofen treatment

December 13, 2022
Distinct NICU newborn naming linked to reduced error
Pediatrics

Laryngeal mask airway is suitable method for surfactant administration in infants with respiratory distress syndrome

November 3, 2022
Racial, ethnic differences in outcomes of extremely preterm infants decreasing but persistent
Chronic Disease

Organizational factors increase risk of unplanned extubation in neonatal intensive care unit

October 25, 2022
Digital imaging detects sight-threatening retinopathy of prematurity
Obstetrics

Half-dose antenatal betamethasone is inferior to full dose for preventing usage of neonatal surfactant

August 31, 2022
Next Post
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

Higher religious adherence may be associated with lower mortality

Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options